America’s Frontline Physicians Endorse Hydroxychloroquine, Face Censorship

In late July, a group of physicians calling themselves America’s Frontline Doctors held a news conference on the steps of the U.S. Supreme Court building in Washington to discuss their experience in treating Covid19.

The group explained their success with patients in the early stages of the disease, where they said they get nearly 100 percent effectiveness. The physicians all prescribed 200 mg of hydroxychloroquine twice a day plus azithromycin (zpac), and zinc.

The live broadcast was viewed by 18 million people in the United States — one of the largest live broadcasts in the history of Facebook.  Immediately, social platforms Facebook, YouTube and Twitter began to systematically remove all traces of the news conference from their platforms.

For example, the Central City News posted to Facebook a link to the news conference as it was going on. Shortly thereafter, Facebook deleted the Central City News post, saying it was false. Since the physicians were simply telling their personal experiences using the drugs, it was difficult to understand how Facebook could claim the statements were false.

Over the next few days, millions of Facebook, YouTube, and Twitter subscribers had their videos and other posts about hydroxychloroquine deleted.  Some people even had their entire page deleted.

It was a very broad and amazing attempt to shut down a discussion of the benefits of hydroxychloroquine.

Many people tried repeatedly to post the video from America’s Frontline Doctors, but in almost every case, the posts were deleted.

The Central City News has many Facebook pages and attempted to post the news conference on all of them.  Only a couple slipped through the fingers of the Facebook censors.

Meanwhile, Central City News was able to get a copy of the video and post it at centralcitynews.us, where it remains beyond the reach of Facebook censors.  To watch it, go to the newspaper website.

Twitter Digg Delicious Stumbleupon Technorati Facebook Email

No comments yet... Be the first to leave a reply!